Apply clinical standard of care in the management of bleeding from access to selective anticoagulation reversal agents to effective overall supportive bleeding management strategies

Evaluate approaches to manage immune-related adverse effects associated with immune checkpoint inhibitors in patients with genitourinary cancer, including renal cell and bladder cancer.

Describe the latest clinical guidelines and recommendations for the use of proprotein convertase subtilisin kexin type 9 inhibitors (PCKS9i)

Apply updated efficacy and safety data, recent guidelines, and individual patient characteristics, such as comorbidities, when making treatment decisions for patients with idiopathic pulmonary fibrosis.

Evaluating the Nonspecific Symptoms of ILD: Guideline-based Strategies for Earlier Detection of IPF

Outline the benefits, indications, and role of continuous glucose monitoring (CGM) in optimizing glycemic control in patients with T2DM

Compare and contrast the safety and efficacy of disease-modifying therapies used in relapsing-remitting MS to current and emerging treatment options for progressive MS

Identify the neurologic, autonomic, cardiac symptoms of hATTR amyloidosis in the context of the differential diagnosis for hATTR amyloidosis

Immuno-oncology for bladder cancer has been around for more than four decades in the form of BCG intravesical therapy for NMIBC. For more advanced disease, systemic platinum-based chemotherapy has been the standard first-line treatment.